Ordering
Available Variants50 mg
CHA.40698-50mg
Price
€94.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.40698-50mg | €94.80 |
analytical standard
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Linear Formula | C2H7NO3PSNa |
|---|---|
| CAS Number | 3724-89-8 |
| Molecular Weight | 179.11 |
| NACRES | NA.24 |
| PubChem Substance ID | 329775169 |
| UNSPSC Code | 41116107 |
| EC Number | 223-079-5 |
| MDL number | MFCD00038474 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H315,H319,H335 |
| pcodes | P261 - P264 - P271 - P301 + P312 - P302 + P352 - P305 + P351 + P338 |
| Hazard Classifications | Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| target_organs | Respiratory system |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Gloves |
Technical Overview & Applications Use-case context
Cysteamine S-phosphate sodium salt, with the CAS number 3724-89-8, is a pharmaceutical compound utilized in the treatment of cystinosis, a rare genetic disorder characterized by the accumulation of cystine within cells. This salt form of cysteamine is administered orally to patients, where it is converted into cysteamine, the active moiety, which then facilitates the reduction of cystine levels. The mechanism of action involves the cleavage of the disulfide bond in cystine, resulting in the formation of cysteine and a cysteamine-cysteine mixed disulfide, thereby reducing cystine accumulation and mitigating the associated cellular damage. As a result, cysteamine S-phosphate sodium salt has been shown to slow disease progression and improve the quality of life for patients with cystinosis, making it a vital component of their therapeutic regimen. Its efficacy and safety profile have been established through extensive clinical trials and research studies.
